Small Pox Vaccine

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Emergent Biodefense Operations Lansing LLC.
The Government intends to purchase 9 Million doses of Food And Drug Administration (FDA) licensed ACAM2000 Smallpox Vaccine, at the time of award with the option to purchase 66 additional doses. This contract will have a 12 month base period and four 12 month option periods. Emergent is the only FDA licensed provider of ACAM2000 Smallpox Vaccine and therefore is the only source capable to provide this requirement to the Government. Emergent's manufacturing processes have been validated and are approved by the FDA, (STN 125158, License #1815). The Government intends to negotiate this requirement under the authority of FAR 6.302-1. It is the Government's belief that only one responsible source exists and no other product or services will satisfy agency requirements.

This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses must be received by August 30, 2018 at 8:00 AM Eastern Standard Time. All responses must be in writing and can be sent via email to srandall@cdc.gov. No phone calls will be accepted.

.